The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...

The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar ...